{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:56:18Z","timestamp":1782266178645,"version":"3.54.5"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T00:00:00Z","timestamp":1241308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> To determine the prevalence of joint and nail symptoms, impact of these symptoms on health\u2010related quality of life (HR\u2010QoL), and the effects of etanercept on them in patients with moderate\u2010to\u2010severe plaque psoriasis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In CRYSTEL, patients with psoriasis received etanercept continuously (<jats:italic>n<\/jats:italic>\u00a0=\u00a0357) or as paused therapy (<jats:italic>n<\/jats:italic>\u00a0=\u00a0363) for 54 weeks. In post hoc analyses, baseline characteristics and after\u2010treatment changes were evaluated in patients with baseline joint pain or nail psoriasis, pooling across treatment groups. Assessments of symptom severity and HR\u2010QoL included the Subject Global Assessment question on joint pain, NAPSI, DLQI and EQ\u20105D.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of 711 patients, 64% reported joint pain and 79% nail psoriasis at baseline. Patients with baseline joint pain or nail psoriasis had significantly worse HR\u2010QoL than unaffected patients. Mean baseline differences between patients with and without joint pain in DLQI (3.3), EQ\u20105D utility (0.2), and EQ\u20105D VAS (7.3) were clinically meaningful. In patients with nail psoriasis, a clinically meaningful difference in EQ\u20105D VAS (5.0) was seen. Etanercept significantly improved symptom severity and HR\u2010QoL. Patients with joint pain had improvements of 47%, 61%, 29%, and 23% in mean joint pain score, DLQI, EQ\u20105D utility, and EQ\u20105D VAS, respectively, at Week 54. Patients with nail psoriasis had improvements of 51%, 63%, and 24% in NAPSI, DLQI, and EQ\u20105D VAS.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In this study of moderate\u2010to\u2010severe plaque psoriasis, joint and nail symptoms were prevalent and patients with these symptoms had significantly greater HR\u2010QoL impairment at baseline than unaffected patients. Etanercept provided significant improvement in symptom severity and HR\u2010QoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflict of Interest<\/jats:title><jats:p>T. Luger has acted as a paid consultant to and speaker for Wyeth Pharmaceuticals. J. Barker has acted as a paid consultant to and speaker for, and has received unrestricted research or education support from Wyeth Pharmaceuticals. J. Lambert has acted as a paid consultant to and speaker for Wyeth. S. Yang, D. Robertson, J. Foehl, C. Molta, and R. Boggs are employed by Wyeth Pharmaceuticals, which supported this study financially.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03211.x","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T04:02:46Z","timestamp":1241409766000},"page":"896-904","source":"Crossref","is-referenced-by-count":94,"title":["Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate\u2010to\u2010severe psoriasis"],"prefix":"10.1111","volume":"23","author":[{"given":"TA","family":"Luger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Foehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CT","family":"Molta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7564.380"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701364768"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948130"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"e_1_2_6_10_2","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire","volume":"29","author":"Alenius G\u2010M","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_2","first-page":"315","article-title":"The epidemiology of joint complaints in patients with psoriasis","volume":"12","author":"Stern RS","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1992.tb02696.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075101"},{"key":"e_1_2_6_14_2","volume-title":"Plaque Psoriasis Patients with More Than 10 Years of Disease History are Almost 5 Times More Likely to Have Psoriatic Arthritis than Those with Less Than 5 Years of Disease","author":"Christophers E","year":"2007"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809020-00004"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30876-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh198"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.4.246"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_6_24_2","unstructured":"Van De KerkhofP SegaertS LahfaMet\u00a0al.Once weekly administration of etanercept 50\u00a0mg is efficacious and well tolerated in patients with moderate\u2010to\u2010severe plaque psoriasis.Br J Dermatol2008[Epub ahead of print]. Available at:http:\/\/www3.interscience.wiley.com\/cgi\u2010bin\/fulltext\/121358845\/HTMLSTART(last accessed 12 August 2008)"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.3.6.657"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03112.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-53"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06502.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-71"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_6_35_2","volume-title":"UK Population Norms for EQ\u20105D (Measurement and Valuation of Health National Survey)","author":"Kind P","year":"1999"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107501"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000069942"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05697.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X178757"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.05.004"},{"key":"e_1_2_6_42_2","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos Y","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.03.046"},{"key":"e_1_2_6_44_2","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982\u201391","volume":"27","author":"Shbeeb M","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0307-1"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00001"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.001"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03211.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03211.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:00:01Z","timestamp":1697061601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03211.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,6]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03211.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03211.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,6]]}}}